The primary goal of the Ph.D. Training Program in Molecular Pharmacology and Experimental Therapeutics (MPET) in the Mayo Graduate School is the development of independent investigators capable of directing outstanding research Programs in academia, industry or other settings. The faculty is comprised of 28 well- funded, independent investigators, who focus on a continuum of research areas encompassing studies from basic molecular and genetic aspects of disease through drug discovery and development of novel therapies for cardiovascular and malignant diseases. The faculty provides training opportunities in areas that include computational chemistry, molecular mechanisms of drug action and resistance, metabolomics, novel therapeutic strategies, the genetics of addiction, preclinical and clinical pharmacology, and pharmacogenomics of genes associated with drug responses. Twenty-six predoctoral students are currently enrolled in the MPET Ph.D. training program. A rigorous didactic curriculum includes a series of Core Curriculum courses that ensures a strong fundamental knowledge in biochemistry, molecular biology, genetics, statistics, cell biology and pharmacology and a series of tutorial-based courses to provide students with advanced training in molecular pharmacology. During their first two years of study, students complete at least 3 laboratory rotations and select a laboratory for their thesis research. They sit for comprehensive written and oral qualifying examinations at the end of year two. After developing a written thesis proposal delineating the questions and approaches to be pursued in the thesis research, the thesis committee reviews the proposed research at the first committee meeting. Student's present work-in-progress updates on their research projects to MPET faculty and students each year. Students are required to publish completed work in a timely manner and encouraged to attend national meetings to present their work. The average time to completion of the Ph.D. Program is 5.2 years. Starting in Year 3 and beyond, students meet with their thesis committees at least twice per year and are mentored to identify outstanding postdoctoral training opportunities as the next step in their career development. Graduates of the MPET Ph.D. training program have outstanding track records. They go on to postdoctoral fellowships, with many now serving as principal investigators in academia and industry. We request 4 positions for the next funding period.
For over three decades the Mayo Clinic Graduate School Ph.D. training program in Molecular Pharmacology and Experimental Therapeutics (MPET) has been training outstanding researchers with the interdisciplinary background and skills to make exciting basic research discoveries and then propel them toward novel therapies for human diseases. We are requesting funding to support a program with a track record of producing outstanding scientists.
|Theis, Jeanne L; Zimmermann, Michael T; Larsen, Brandon T et al. (2014) TNNI3K mutation in familial syndrome of conduction system disease, atrial tachyarrhythmia and dilated cardiomyopathy. Hum Mol Genet 23:5793-804|
|Kapplinger, Jamie D; Landstrom, Andrew P; Bos, J Martijn et al. (2014) Distinguishing hypertrophic cardiomyopathy-associated mutations from background genetic noise. J Cardiovasc Transl Res 7:347-61|
|Sainski, Amy M; Dai, Haiming; Natesampillai, Sekar et al. (2014) Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation. J Cell Biol 207:159|
|Hartjes, Katherine A; Li, Xing; Martinez-Fernandez, Almudena et al. (2014) Selection via pluripotency-related transcriptional screen minimizes the influence of somatic origin on iPSC differentiation propensity. Stem Cells 32:2350-9|
|Huntoon, Catherine J; Flatten, Karen S; Wahner Hendrickson, Andrea E et al. (2013) ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res 73:3683-91|
|Patel, Anand G; Flatten, Karen S; Schneider, Paula A et al. (2012) Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. J Biol Chem 287:4198-210|
|Patel, Anand G; De Lorenzo, Silvana B; Flatten, Karen S et al. (2012) Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res 18:1655-62|
|Patel, Anand G; Sarkaria, Jann N; Kaufmann, Scott H (2011) Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 108:3406-11|
|Dai, Haiming; Smith, Alyson; Meng, X Wei et al. (2011) Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. J Cell Biol 194:39-48|
|Huehls, Amelia M; Wagner, Jill M; Huntoon, Catherine J et al. (2011) Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells. Cancer Res 71:4944-54|
Showing the most recent 10 out of 11 publications